Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 25;6(2):e001314. doi: 10.1136/rmdopen-2020-001314

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Reorganisation of rheumatology care during the COVID-19 pandemic.

Sequential steps of organising rheumatology care throughout the coronavirus disease 19 (COVID-19) pandemic. Phase I addresses the initial response to the context of widespread community transmission of SARS-CoV-2, with major travel and social restrictions. Phase II refers to the adaptation taking place over the following months, as restrictions are slowly lifted and an effective vaccine is not yet available. Finally, phase III anticipates the prospect of post-COVID-19 rheumatology. AE, adverse effects; bDMARDs, biologic disease-modifying anti-rheumatic drugs; DMARDs, disease-modifying anti-rheumatic drugs; HCW, healthcare worker; IV, intravenous; PPE, personal protective equipment; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sc, subcutaneous; tsDMARDs, targeted synthetic disease-modifying anti-rheumatic drugs; VPN, virtual private network.